Working… Menu

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02495896
Recruitment Status : Active, not recruiting
First Posted : July 13, 2015
Last Update Posted : April 5, 2021
National Cancer Institute (NCI)
Vasgene Therapeutics, Inc
Information provided by (Responsible Party):
University of Southern California

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : December 3, 2024